CORT

+ Watchlist + Portfolio

Corcept Therapeutics Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $119.02
52-Week Range: $28.66 – $122.21
Market Cap: $13.09B
P/E (TTM): 269.00
EPS (TTM): 0.45
Dividend Yield: —

Advanced Metrics

Price/Book: 18.51
PEG Ratio: 0.81
Return on Equity: 8.23%
Return on Assets: 0.47%
Gross Margin: 98.30%
Operating Margin: 16.12%
Profit Margin: 6.64%
Current Ratio: 2.86
Debt/Equity: 0.01
Total Debt: $9.42M
Free Cash Flow: $77.40M
Revenue Growth: 31.70%
Earnings Growth: 24.10%
Enterprise Value: $12.79B

CORT Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$401.86M	$482.38M	$675.04M	$761.41M
Cost of Revenue	$5.38M	$6.48M	$10.88M	$12.98M
Gross Profit	$396.47M	$475.89M	$664.16M	$748.43M
Research & Development	$130.99M	$184.35M	$246.89M	$254.91M
Selling, General & Admin	$152.85M	$184.26M	$280.32M	$448.73M
Operating Expenses	$283.84M	$368.61M	$527.21M	$703.63M
Operating Income	$112.63M	$107.28M	$136.95M	$44.80M
EBITDA	$116.08M	$109.64M	$138.29M	$46.69M
Pretax Income	$116.19M	$124.56M	$161.49M	$66.46M
Income Tax	$14.77M	$18.42M	$20.28M	-$33.19M
Net Income	$101.42M	$106.14M	$141.21M	$99.65M
Diluted EPS	0.87	0.94	1.23	0.82
Diluted Shares	115.97M	111.74M	113.48M	119.99M

CORT Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$66.33M	$135.55M	$127.67M	$120.50M
Receivables	$45.06M	$55.12M	$53.98M	$59.79M
Inventory	$6.10M	$7.73M	$12.41M	$12.87M
Current Assets	$499.25M	$458.64M	$471.60M	$485.46M
Total Assets	$583.43M	$621.52M	$840.55M	$836.65M
Current Liabilities	$72.49M	$104.50M	$140.77M	$166.09M
Total Debt	$1.14M	$151.00K	$6.94M	$6.11M
Total Liabilities	$81.59M	$114.81M	$160.96M	$188.85M
Retained Earnings	$296.39M	$402.53M	$543.74M	$643.39M
Shareholders' Equity	$501.84M	$506.70M	$679.59M	$647.80M
Working Capital	$426.76M	$354.13M	$330.83M	$319.38M

CORT Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$120.32M	$126.68M	$198.29M	$142.00M
Capital Expenditure	-$413.00K	-$139.00K	-$2.17M	-$211.00K
Free Cash Flow	$119.91M	$126.54M	$196.12M	$141.78M
Depreciation & Amortisation	$3.45M	$2.36M	$1.34M	$1.89M
Stock-Based Compensation	$42.44M	$48.94M	$61.35M	$84.50M
Investing Cash Flow	-$114.33M	$90.91M	-$177.60M	$69.76M
Financing Cash Flow	-$17.28M	-$148.72M	-$28.35M	-$220.37M
Share Repurchases	$0.00	-$145.43M	$0.00	$0.00
Net Change in Cash	-$11.29M	$68.86M	-$7.66M	-$8.61M

CORT Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$194.43M	$207.64M	$202.13M	$164.90M	$256.15M
Cost of Revenue	$3.43M	$4.60M	$2.54M	$2.88M	$4.06M
Gross Profit	$191.00M	$203.04M	$199.58M	$162.02M	$252.09M
Research & Development	$60.47M	$68.85M	$64.86M	$66.27M	$53.89M
Selling, General & Admin	$103.85M	$123.98M	$130.24M	$145.36M	$156.90M
Operating Expenses	$164.32M	$192.82M	$195.09M	$211.62M	$210.79M
Operating Income	$26.68M	$10.22M	$4.49M	-$49.60M	$41.30M
EBITDA	$27.14M	$10.70M	$4.97M	-$49.00M	$42.16M
Pretax Income	$31.69M	$15.24M	$9.91M	-$44.72M	$45.93M
Income Tax	-$3.46M	-$4.42M	-$14.38M	-$12.95M	$2.94M
Net Income	$35.15M	$19.67M	$24.29M	-$31.76M	$42.99M
Diluted EPS	0.29	0.16	0.20	-0.30	0.36
Diluted Shares	120.48M	119.44M	119.86M	104.44M	118.39M

CORT Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$102.75M	$125.14M	$120.50M	$108.74M	$111.04M
Receivables	$64.57M	$69.63M	$59.79M	$39.07M	$76.92M
Inventory	$12.28M	$12.35M	$12.87M	$12.89M	$13.19M
Current Assets	$443.11M	$541.13M	$485.46M	$426.03M	$439.68M
Total Assets	$801.72M	$823.61M	$836.65M	$814.88M	$888.70M
Current Liabilities	$144.66M	$172.26M	$166.09M	$149.19M	$153.80M
Total Debt	$6.61M	$6.36M	$6.11M	$9.64M	$9.42M
Total Liabilities	$165.93M	$191.71M	$188.85M	$176.89M	$182.93M
Retained Earnings	$599.43M	$619.10M	$643.39M	$611.63M	$654.61M
Shareholders' Equity	$635.79M	$631.90M	$647.80M	$637.99M	$705.78M
Working Capital	$298.45M	$368.87M	$319.38M	$276.85M	$285.87M

CORT Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$44.30M	$54.48M	$38.45M	-$16.77M	$33.54M
Capital Expenditure	-$57.00K	—	-$50.00K	-$201.00K	-$2.53M
Free Cash Flow	$44.24M	$54.48M	$38.40M	-$16.97M	$31.02M
Depreciation & Amortisation	$469.00K	$477.00K	$482.00K	$598.00K	$863.00K
Stock-Based Compensation	$19.02M	$22.88M	$20.77M	$23.04M	$29.42M
Investing Cash Flow	$70.13M	$14.64M	-$11.84M	$4.54M	-$29.24M
Financing Cash Flow	-$102.93M	-$46.41M	-$31.22M	$760.00K	-$2.04M
Net Change in Cash	$11.49M	$22.71M	-$4.61M	-$11.47M	$2.26M

Market Snapshot

About

Corcept Therapeutics Inc. is a pharmaceutical company focused on the discovery and development of medications to treat severe metabolic, oncologic, and psychiatric disorders by modulating the effects of cortisol. Headquartered in Menlo Park, California, the company's lead product is Korlym (mifepristone), approved for treating Cushing's syndrome, a rare disease caused by excess cortisol. Corcept has a pipeline of selective cortisol modulators in development for various conditions including ovarian cancer, prostate cancer, and antipsychotic-induced weight gain. The company holds extensive intellectual property around cortisol modulation therapies.